Denali Advisors LLC Has $1.74 Million Stake in Novartis AG $NVS

Denali Advisors LLC lowered its stake in shares of Novartis AG (NYSE:NVS) by 37.8% in the third quarter, according to its most recent disclosure with the SEC. The fund owned 13,559 shares of the company’s stock after selling 8,254 shares during the period. Denali Advisors LLC’s holdings in Novartis were worth $1,739,000 as of its most recent filing with the SEC.

Other institutional investors have also added to or reduced their stakes in the company. Legacy Investment Solutions LLC bought a new stake in shares of Novartis in the 2nd quarter worth approximately $30,000. Valley Wealth Managers Inc. bought a new position in Novartis in the third quarter worth $31,000. Country Trust Bank boosted its stake in Novartis by 47.4% during the third quarter. Country Trust Bank now owns 342 shares of the company’s stock worth $44,000 after buying an additional 110 shares in the last quarter. Quaker Wealth Management LLC boosted its stake in Novartis by 200.0% during the second quarter. Quaker Wealth Management LLC now owns 352 shares of the company’s stock worth $43,000 after buying an additional 704 shares in the last quarter. Finally, Evelyn Partners Investment Management LLP increased its holdings in Novartis by 28.0% in the 2nd quarter. Evelyn Partners Investment Management LLP now owns 448 shares of the company’s stock valued at $54,000 after buying an additional 98 shares during the period. 13.12% of the stock is owned by institutional investors and hedge funds.

Novartis Trading Up 1.2%

Shares of NYSE NVS opened at $163.09 on Tuesday. Novartis AG has a 1-year low of $97.71 and a 1-year high of $163.42. The company has a 50-day moving average of $144.17 and a two-hundred day moving average of $132.86. The company has a market cap of $344.52 billion, a PE ratio of 22.78, a P/E/G ratio of 2.45 and a beta of 0.50. The company has a current ratio of 1.12, a quick ratio of 0.89 and a debt-to-equity ratio of 0.60.

Novartis (NYSE:NVS) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $2.03 earnings per share for the quarter, beating analysts’ consensus estimates of $1.99 by $0.04. Novartis had a net margin of 25.65% and a return on equity of 40.53%. The business had revenue of $524.00 million during the quarter, compared to analyst estimates of $13.85 billion. During the same quarter last year, the business posted $1.98 earnings per share. Novartis’s revenue for the quarter was up 1.4% compared to the same quarter last year. As a group, equities analysts expect that Novartis AG will post 8.45 earnings per share for the current fiscal year.

Novartis Dividend Announcement

The company also recently declared an annual dividend, which will be paid on Monday, March 16th. Stockholders of record on Wednesday, March 11th will be paid a dividend of $4.773 per share. This represents a dividend yield of 312.0%. The ex-dividend date of this dividend is Wednesday, March 11th. Novartis’s dividend payout ratio is 36.31%.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on NVS shares. Jefferies Financial Group reissued a “hold” rating on shares of Novartis in a research note on Monday, October 27th. HSBC reissued a “reduce” rating and issued a $112.00 target price on shares of Novartis in a report on Wednesday, December 10th. Cfra set a $126.00 price target on Novartis and gave the company a “hold” rating in a research report on Wednesday, October 29th. TD Cowen reiterated a “hold” rating on shares of Novartis in a research note on Monday, November 10th. Finally, DZ Bank downgraded shares of Novartis from a “strong-buy” rating to a “hold” rating in a research note on Monday, February 9th. Two equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, six have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $119.75.

Novartis Company Profile

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.